|
시장보고서
상품코드
1563392
마이크로 RNA 시장 규모, 점유율, 성장 분석, 제품 및 서비스별, 용도별, 최종 용도별, 지역별 - 산업 예측(2024-2031년)MicroRNA Market Size, Share, Growth Analysis, By Products & Services, By Application, By End-use, By Region - Industry Forecast 2024-2031 |
||||||
세계 마이크로 RNA 시장 규모는 2022년 12억 달러로 2023년 13억 5,000만 달러에서 2031년까지 35억 8,000만 달러로 성장할 것으로 예상되며, 예측 기간(2024-2031년) 동안 12.90%의 CAGR로 성장할 것으로 예상됩니다.
세계 마이크로RNA 시장은 분자생물학, 유전체학, 생물정보학의 발전에 힘입어 최근 괄목할 만한 성장을 거듭하고 있습니다. 마이크로RNA(miRNA)는 유전자 발현 조절에 필수적인 저분자 비암호화 RNA 분자로, 다양한 질병의 귀중한 바이오마커이자 새로운 치료법의 잠재적 표적으로 자리매김하고 있습니다. 진단 및 치료에서의 miRNA의 가능성과 함께 질병 과정에서 miRNA의 역할에 대한 이해도가 높아진 것이 시장 확대의 큰 원동력이 되고 있습니다. 암, 심혈관계 질환, 신경계 질환 등 만성질환의 증가는 miRNA가 질병의 진단, 예후, 치료에 있어 유망하다는 점에서 이 분야에 대한 연구와 투자 증가로 이어져 이러한 성장을 더욱 촉진하고 있습니다. 또한, 차세대 시퀀싱 및 마이크로어레이 플랫폼과 같은 기술의 발전은 miRNA의 프로파일링 및 검출을 향상시켜 시장 개척을 촉진하고 있습니다. 그러나 miRNA 기반 치료제 및 진단약에 대한 복잡한 규제 환경, 엄격한 요건과 비용이 많이 드는 임상시험, miRNA 기반 제품의 안전성, 유효성 및 특이성을 보장하는 것이 매우 중요하다는 점 등 여러 가지 도전 과제에 직면해 있습니다. 하지만 많은 어려움이 있습니다. 또한, miRNA의 기능과 생물학적 시스템 내 상호작용에 대한 이해가 제한적이라는 점도 연구를 복잡하게 만들고, miRNA 치료제의 효과적인 전달 시스템 개발은 표적에 대한 전달과 안정성의 필요성에서 비롯된 도전 과제입니다. 이러한 장애물에도 불구하고, 세계 마이크로RNA 시장은 성장과 혁신의 큰 기회를 가지고 있으며, 기술 발전, 연구 증가 및 공동연구가 새로운 miRNA 기반 진단 및 치료법 개발을 촉진할 것으로 예상됩니다.
Global MicroRNA Market size was valued at USD 1.20 billion in 2022 and is poised to grow from USD 1.35 billion in 2023 to USD 3.58 billion by 2031, growing at a CAGR of 12.90% during the forecast period (2024-2031).
The global microRNA market has experienced notable growth recently, fueled by advances in molecular biology, genomics, and bioinformatics. MicroRNAs (miRNAs) are small non-coding RNA molecules essential for regulating gene expression, positioning them as valuable biomarkers for various diseases and potential targets for new therapies. Increased understanding of miRNA's role in disease processes, alongside its potential in diagnostics and treatments, has significantly driven market expansion. The rise in chronic diseases, such as cancer, cardiovascular conditions, and neurological disorders, further supports this growth, as miRNAs show promise in disease diagnosis, prognosis, and treatment, leading to more research and investment in the field. Additionally, advancements in technologies like next-generation sequencing and microarray platforms have enhanced miRNA profiling and detection, boosting market development. However, the market faces several challenges. Navigating the complex regulatory landscape for miRNA-based therapeutics and diagnostics is a major hurdle, with stringent requirements and costly clinical trials. Ensuring the safety, efficacy, and specificity of miRNA-based products is critical but challenging. Limited understanding of miRNA functions and their interactions within biological systems also complicates research. Developing effective delivery systems for miRNA therapeutics is another challenge due to the need for targeted delivery and stability. Despite these obstacles, the global microRNA market holds substantial opportunities for growth and innovation, with technological advancements, increased research, and collaborative efforts expected to drive the development of new miRNA-based diagnostics and treatments.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global MicroRNA market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global MicroRNA Market Segmental Analysis
Global MicroRNA Market is segmented by Products & Services, Application, End-use, and region. Based on Products & Services, the market is segmented into services, and products. Based on Application, the market is segmented into Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease, and Others. Based on End-use, the market is segmented into Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.
Drivers of the Global MicroRNA Market
Recent technological strides in genomics and molecular biology, particularly through next-generation sequencing and microarray platforms, have revolutionized the analysis of microRNAs. These advanced tools facilitate high-throughput examination, allowing researchers to identify and characterize microRNAs with greater efficiency. As a result, the capabilities of these technologies have spurred a surge in research activities, significantly contributing to the expansion of the microRNA market. The enhanced ability to analyze microRNAs has opened new avenues for discovery and innovation, further propelling market growth.
Restraints in the Global MicroRNA Market
Despite extensive research on microRNAs, their exact functions and mechanisms remain incompletely understood. This gap in knowledge presents challenges in pinpointing reliable and specific biomarkers, as well as in creating effective therapeutic strategies. The ongoing uncertainty surrounding microRNA biology complicates efforts to develop precise diagnostic and treatment options. Addressing these gaps is crucial for advancing the field and fully leveraging the potential of microRNAs in clinical applications.
Market Trends of the Global MicroRNA Market
Partnerships among biotechnology and pharmaceutical companies, academic research institutions, and government agencies are becoming more prevalent in the field of microRNA research. These collaborations combine the expertise, resources, and insights of various stakeholders, aiming to expedite the development and market introduction of microRNA-based products and solutions. By pooling their strengths, these collaborative efforts enhance the efficiency of research and development processes, driving innovation and accelerating the advancement of microRNA technologies. This collective approach supports the rapid commercialization and broader application of microRNA-based advancements.